FDA sends a wave of warning letters over GLP-1 ads from online clinics
The agency said many online sellers implied compounded copies were the same as approved drugs, and told them to fix their marketing.
Who feels it
-
Sellers
Rethink
Online sellers had to rewrite claims about compounded products.
-
Patients
Worth knowing
An ad that says “same as” a brand may not be true; ask what you are actually getting.
-
Prescribers
Worth knowing
Patients may ask whether what they saw online is the real drug.
-
Pharmacies
Worth knowing
Pharmacies that supply telehealth brands may be asked to review claims.
-
Payers
Passes by
No direct effect.
What the FDA did
In September 2025 the FDA announced a crackdown on misleading drug advertising. It sent warning and untitled letters to many companies, including telehealth firms and compounders marketing GLP-1 copies.
What the letters said
The agency said some ads suggested compounded products were the same as approved drugs, or left out risk information. Compounded drugs are not approved by the FDA for safety or effectiveness.
Why it matters
Online clinics grew quickly by advertising low prices for “semaglutide” or “tirzepatide.” The letters told them that how they describe what they sell is now under close watch.
What to look for
Ads that use brand names, before-and-after claims, or no mention of risk are the kind the agency targeted.
Source US Food and Drug Administration announcements on drug advertising enforcement, September 2025
Spotted an error? Tell us through the contact form; we follow the corrections policy.
